Lexicon Pharmaceuticals, Inc.
NASDAQ:LXRXBiotechnology
-$0.05 today
- Market cap
- $765.80M
- Beta
- 1.07
- P/E (TTM)
- -30.5
- EPS (TTM)
- -$0.07
Volume 2.02M
Average 2.48M
LXRX Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
Lexicon Pharmaceuticals, Inc.NASDAQ: LXRX
Revenue · Q1 FY2026 · quarter ended Mar 2026
Revenue growth accelerates
Q1 FY2026 revenue of $21.1M rose 1572.1% year over year, ahead of the +123.1% change in trailing-twelve-month revenue. Sequentially, it rose 284.2% from the prior quarter. Over 3 fiscal years it compounded at +610.3% a year.
Context
- Revenue increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether revenue reaches the consensus estimate from 4 analysts of $37.4M (-24.9%) for the fiscal year ending Dec 2026, a slowdown from the +60.2% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $21.1M+284.2% QoQ
- Last fiscal yearDec 2025
- $49.8M+60.2% YoY
- LTMMar 2026
- $69.64M+123.1% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +1572.1% | -86.2% | -1658.3 pp |
| 1 year | +60.2% | -24.9% | -85.1 pp |
| 3-year CAGR | +610.3% | +15.0% | -595.2 pp |
| 5-year CAGR | +39.1% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 49.8M USD
- Year-over-year change
- +60.2%
- 4-year CAGR
- +259.6%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 49.8M | +60.2% |
| FY2024 | 2024-12-31 | 31.08M | +2481.5% |
| FY2023 | 2023-12-31 | 1.2M | +766.2% |
| FY2022 | 2022-12-31 | 139K | -53.4% |
| FY2021 | 2021-12-31 | 298K | — |
Revenue vs competitors
How LXRX compares with its peers on the latest reported figures
- LXRX's LTM Mar 2026 revenue of $69.64M is the 6th highest of the 11 companies compared; the peer median is $153.44M.
- Its year-over-year change of +123.1% is the 2nd highest of 7, against a peer median of +34.4%.
- Over three fiscal years its annual growth of +610.3% compares with a peer median of +41.6%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Jun 2026 | $1.01B | -42.8% | +35.3% | |
| LTM Sep 2026 | $959.76M | -0.7% | +17.1% | |
| LTM Jun 2026 | $940.61M | +68.7% | +47.8% | |
| LTM Mar 2026 | $360.78M | +21.2% | +51.8% | |
| LTM Mar 2026 | $299.77M | +47.6% | +34.8% | |
| LTM Mar 2026 | $69.64M | +123.1% | +610.3% | |
| LTM Mar 2026 | $7.12M | +1199.6% | +69.0% | |
| LTM Sep 2026 | $0 | — | — | |
| LTM Mar 2026 | $0 | — | — | |
| LTM Mar 2026 | $0 | — | — | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $0 | — | — |
| Peer median (excluding LXRX) | $153.44M | +34.4% | +41.6% | |
Competitors are the stored peer set for LXRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 298K | 139K | 1.2M | 31.08M | 49.8M |
| Cost of Revenue | 55.05M | 52.52M | 58.97M | 616K | 274K |
| Gross Profit | (54.75M) | (52.38M) | (57.77M) | 30.47M | 49.53M |
| Gross Margin | -18371.8% | -37681.3% | -4798.0% | 98.0% | 99.4% |
| Research & Development | 55.05M | 52.82M | 58.89M | 84.48M | 61.12M |
| Selling, General & Admin | 0 | 0 | 0 | 131.9M | 37.32M |
| Operating Expenses | 32.34M | 48.38M | 113.98M | 227.58M | 98.44M |
| Depreciation & Amortization | 292K | 427K | 554K | 534K | 621K |
| EBITDA | (86.66M) | (100.03M) | (169.76M) | (184.29M) | (41.38M) |
| EBITDA Margin | -29081.9% | -71966.2% | -14099.3% | -592.9% | -83.1% |
| Operating Income | (87.09M) | (100.76M) | (171.75M) | (197.12M) | (48.91M) |
| Operating Margin | -29224.8% | -72489.2% | -14265.0% | -634.2% | -98.2% |
| Interest Income | 134K | 1.6M | 7.73M | 12.29M | 6.91M |
| Interest Expense | 802K | 2.78M | 13.1M | 15.58M | 8.34M |
| Other Income / Expenses | (668K) | (1.18M) | (5.37M) | (3.29M) | (1.43M) |
| Income Before Tax | (87.76M) | (101.94M) | (177.12M) | (200.4M) | (50.34M) |
| Pre-Tax Margin | -29449.0% | -73341.0% | -14710.9% | -644.8% | -101.1% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (87.76M) | (101.94M) | (177.12M) | (200.4M) | (50.34M) |
| Net Margin | -29449.0% | -73341.0% | -14710.9% | -644.8% | -101.1% |
| EPS (Basic) | (0.61) | (0.62) | (0.80) | (0.63) | (0.14) |
| EPS (Diluted) | (0.61) | (0.62) | (0.80) | (0.63) | (0.14) |
| Weighted Avg Shares | 145.65M | 165.73M | 221.13M | 320.03M | 363.05M |
| Weighted Avg Shares (Diluted) | 145.65M | 165.73M | 221.13M | 320.03M | 363.05M |
Lexicon Pharmaceuticals, Inc.
NASDAQ:LXRX
Intrinsic Alpha fair value
Locked
Current Price
$1.72
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.